GM2A and Alzheimer disease: GM2A has shown promise as a CSF biomarker for neurodegeneration in AD, correlating with CSF amyloid-beta levels, and in Lewy body dementia (LBD) with increased concentration [36], whilst the concentration in PD has shown to be reduced [37].